US Pharma MarketingImmunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails
Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Immunovant has confirmed that its first-generation FcRn inhibitor has been scrapped, a month after the asset flunked a pair of phase 3 eye disease trials.
Source: FierceBiotech